Retatrutide

Details

Retatrutide is a once-weekly subcutaneous triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors. It is being developed by Eli Lilly for chronic weight management and obesity-related complications. The addition of glucagon receptor agonism increases energy expenditure and hepatic fat oxidation alongside the appetite-suppressing and insulinotropic effects of GIP and GLP-1 agonism. In the phase 3 TRIUMPH-1 trial, retatrutide produced mean weight reductions of 17.6–25.0% at 80 weeks with the treatment-regimen estimand and up to 28.3% with the efficacy estimand, the largest weight loss reported for any obesity pharmacotherapy to date. (sources/Retatrutide-Obesity-NEJM-2026, rating: very high)

Key Facts

Pharmacology

TRIUMPH-1 — Phase 3 Obesity Trial

Knee Osteoarthritis Basket

Obstructive Sleep Apnea Basket

Cardiometabolic Effects

Safety

Comparison with Other Incretin-Based Therapies

Agent Receptors Weight loss in obesity trials Key cardiovascular data
Semaglutide 2.4 mg GLP-1 ~15–17% at 68 weeks SELECT MACE HR 0.80; STEP-HFpEF KCCQ +7.8
Tirzepatide 15 mg GIP + GLP-1 ~20–22% at 72 weeks SUMMIT HFpEF composite HR 0.62
Retatrutide 12 mg GIP + GLP-1 + glucagon ~25% at 80 weeks; up to 28.3% efficacy estimand No cardiovascular outcome trial yet; TRIUMPH-Outcomes ongoing

Pipeline

Contradictions / Open Questions

Connections

Sources